Description of Invention:
Intranasal or intramuscular inoculations of BALB/c mice with modified vaccinia Ankara (MVA) vector encoding SARS-CoV Spike protein produced serum antibodies that recognized SARS S in ELISA and elicited protective immunity as shown by reduced titers of SARS-CoV in the upper and lower respiratory tracts of mice following challenge. Passive transfer of serum from mice immunized with MVA/S to naive mice also reduced the replication of SARS-CoV in the respiratory tract following challenge, demonstrating the role of antibody to S in protection.
Inventors:
Bernard Moss (NIAID)
Patent Status:
DHHS Reference No. E-165-2004/0 --
U.S. Provisional Application No. 60/558,995 filed 05 Apr 2004
PCT Patent Application No. PCT/US2005/011510 filed 05 Apr 2005, which published as WO 2006/071250 on 06 Jul 2006
Related Technologies: DHHS Reference No. E-334-2003 -- Enhanced Sensitivity ELISA for SARS Diagnostic
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
